Cancer treatment startup collects $80M
February 12, 2021- Share:
Cyteir Therapeutics has secured an $80 million Series C led by RA Capital Management, with support from Janus Henderson Investors, Ally Bridge Group, Acuta Capital Partners and Avidity Partners. Based in the Boston area, the company is a clinical-stage developer of synthetic lethal therapies designed to target cancerous tumor cells while sparing normal cells. Cyteir plans to use the funding in part to advance its lead compound into Phase II trials.
Additional Investors
- Share:
-
-
-
-